Browse by ▼

Merck & Co., Inc.

  • New Sleeping Aid Could Be An Awakening for Merck

    By Diane Alter - May 23, 2013 | Tickers: JNJ, MRK, SNY

    Sleep or lack thereof, is a major problem for millions of individuals.

    A recent review published online in the journal The Lancet found nearly a quarter of all adults are unhappy with their sleep patterns. Meanwhile, some 10% meet the criteria for full-fledged insomnia.

    “Insomnia has traditionally been trivialized,” paper co-author Charles Morin, Ph.D., a sleep researcher and professor at the Universite Laval in Quesbe Citry told the Huffington more »

  • The New Drug Can Make This Stock a Steal

    By Tanya Kanodia - May 23, 2013 | Tickers: BMY, MRK, RHHBY

    Bristol-Myers Squibb (NYSE: BMY) has developed hit drugs for the company and has a well structured R&D program with highly efficient and motivated workforce. The company has taken a hit in the recent times due to patent losses of some of its drugs which led to a loss in profitability. However, Bristol-Myers Squibb has several upcoming drugs in its pipeline which makes it a good long term investment. Here more »

  • Questcor Pharma: Can It Outperform The Market?

    By Amiya Raut - May 23, 2013 | Tickers: MRK, NVS, QCOR

    Overview:

    Questcor Pharmaceuticals, Inc. (Questcor), incorporated November 02, 1990, is an integrated specialty pharmaceutical company focused on the development, acquisition and marketing of innovative, acute care and critical care hospital/specialty pharmaceutical products. The Company is focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders.The company's primary product is H.P. Acthar Gel, an injectable drug used for the treatment of 19 indications including more »

  • 4 Big Drug Companies With Big Juicy Yields

    By David Dierking - May 22, 2013 | Tickers: LLY, MRK, PFE, TEVA

    Drug companies have been revenue generating machines for long. They’re in the enviable position of being able to profit from the aging of America by providing a product that will be in continuous demand. While those revenue streams can hit some peaks and troughs due to things like drug patent expiration (something that Pfizer (NYSE: PFE) will be dealing with shortly with its big name drug Lipitor), the big more »

  • Dividend Stocks Are The New Bonds

    By Timothy Green - May 20, 2013 | Tickers: INTC, MRK, MSFT

    The claim that bonds are safe is a pervasive one. But is it true? It turns out that there are two types of risk associated with bonds. The first, default risk, is the root of the apparent safety of bonds. The likelihood of the US government or major US corporations defaulting on their debt is as close to zero as you can get. But a second kind of risk, interest more »

  • This Stock Should Get Better in the Long Run

    By Terry Chrisomalis - May 15, 2013 | Tickers: ACAD, MRK, PFE

    ACADIA Pharmaceuticals (NASDAQ: ACAD) has been on a solid run since early last year and it has continued to climb to new highs this year as well. The move that started it all happened in late 2012. On Nov. 27, 2012, ACADIA had announced that their drug, Pimavanserin, had met both primary and secondary endpoints. This trial completed was the pivotal phase 3 trial for Parkinson disease Psychosis. 

    So, as more »

  • These Stocks Are Still Solid Long-Term Picks

    By Jarrod Bailey - May 15, 2013 | Tickers: LLY, MRK, PFE

    Confirmation bias – one of the psychological traps investors can be most prone to falling victim to. What happens to us as investors when we are influenced by this bias is we essentially discount all information that counters our established view point. If we are bullish on a particular stock, then confirmation bias will mean we will tend to overemphasize the importance of bullish news relative to bearish news. Confirmation bias more »

  • Why This Pharma Giant Doesn't Look Good Now

    By Sonam Chamaria - May 14, 2013 | Tickers: BMY, MRK, PFE

    Pharmaceutical companies in the U.S. are not having it easy these days. When Johnson & Johnson reported its latest numbers recently, it suffered from currency headwinds. Last week, Merck (NYSE: MRK) announced its first-quarter earnings, managing to beat analyst estimates. Is it stronger than the rest? Or is it in the same boat? Let's find out.

    Going down

    In the previous quarter, Merck's global sales amounted to $10 more »

  • Buying the Pharma Dips

    By Marshall Hargrave - May 13, 2013 | Tickers: BMY, MRK, PFE

    Pfizer (NYSE: PFE) saw a strong pullback earlier this month, with its stock tumbling over 6% after reporting first-quarter earnings results. Meanwhile, fellow drug maker Merck (NYSE: MRK) was down over 4% for similar reasons. Does this present investors with a buying opportunity? Quite possibly so; however, not all drug makers are created equally.
     
    After the pullback, Pfizer trades at 12.3 times forward earnings and Merck at 12 times more »

  • 6 Big Pharma Stocks With Lower Credit Risk Than U.S. Treasuries: Part II

    By Meena Krishnamsetty - May 10, 2013 | Tickers: MRK, NVS, PFE

    The healthcare sector has been known for paying dependable dividends and producing strong total returns over time. Among the major pharmaceutical companies, there are a few that stand out as most financially sound, as reflected by their CDS spreads below those of the U.S. Treasuries.

    This is the second part of our list; the first section included Bristol Myers Squibb, Eli Lilly, and Johnson & Johnson.

    Why use CDS spreads more »

  • London-Based Hedgie Focusing On Big Pharma

    By Meena Krishnamsetty - May 10, 2013 | Tickers: LLY, JNJ, MRK, MSFT, PFE

    By law, institutional investors with over $100 million in investment discretion in Section 13(f), are required within 45 days after the end of a calendar quarter to file the 13F form with the SEC. The 13F form discloses all of the US-listed publicly traded holdings in a fund's equity portfolio. One of the most recent filings belongs to London-based RWC Asset Management LLP. Reading on will take you more »

  • 3 Drug Catalysts to Watch in 2013

    By Brandy Betz - May 9, 2013 | Tickers: MNKD, MRK, PFE, RIGL, SNY

    Pharmaceutical investors: start your engines! We’re into the second quarter of 2013 and some major catalysts lurk right around the corner.

    Merck (NYSE: MRK) has a Food and Drug Administration meeting for a potential first-in-class insomnia treatment. The drug offers a better safety profile than the currently available treatments. MannKind (NASDAQ: MNKD)  returns with additional trial data that has delayed its anticipated diabetes inhalant. And Rigel Pharmaceuticals (NASDAQ: RIGLmore »)

  • Will $15 Billion Work for This Troubled Drug Maker?

    By Nick Chiu - May 9, 2013 | Tickers: MRK, NVS, PFE

    Merck (NYSE: MRK), with a market cap of $138.09 billion, is a global health care company, delivering innovative health solutions through its prescription medicines, vaccines, and biologic therapies, etc.

    Merck does not look good in the near-term with its disappointing revenue and profit that are below analysts’ estimates. Despite the previous downplay, the result still surprised to the down side due to strong generic competitions and unfavorable exchange rates more »

  • The Ups and Downs of Diabetes

    By Tyler Wofford - May 8, 2013 | Tickers: ABT, MRK, NVO

    Recently, I have focused in on some companies that play a major role in diabetic's lives like mine. The financial implications of this disease are astounding, and have presented what seems to be a great opportunity for investors. Today, I will discuss the earnings results of some of the largest players involved with the disease. 

    Let's get the biggest surprise (to me) out of the way. I have more »

  • Healthcare Helps Your Portfolio’s Wellbeing

    By Jeff Stouffer - May 5, 2013 | Tickers: GILD, IYH, JNJ, MRK, PFE

    An allocation to Healthcare investment strategies can be good for the wellbeing of your portfolio. Looking into the iShares Dow Jones US Healthcare Sector Index Fund (NYSEMKT: IYH), an exchange-traded fund, I find a lot of positive results, even with the anchor effect associated with 2008. The one-year return is 30.7%, the three-year return is 17.66% and the five-year return is 10.99%. This ETF was brought to more »

  • 3 Blue Chips with Big Buyback Plans

    By Jordan Wathen - May 2, 2013 | Tickers: HD, IBM, MRK

    2013 is the year of the repurchase program.

    So far this year, major repurchase programs have been announced by some of Wall Street's largest companies. Forget the great rotation – retail investors will find it hard to keep up with the pace of repurchases by the world's largest publicly-traded companies.

    Here are three companies with aggressive repurchase plans.

    IBM (NYSE: IBM)

    Despite weaker-than-expected earnings from Big Blue, IBM announced more »

  • Novartis’ Patent Loss Underscores Future Growth Dangers

    By Peter Pham - May 1, 2013 | Tickers: MRK, NVS, PFE

    In a much hyped and landmark case, Novartis (NYSE: NVS) has had its patent revoked by Indian authorities. Authorities made it clear that India can step forward to revoke drug patents in the occurrence of any serious disease or pandemics.

    The Supreme Court’s ruling on on April 1st came as a blow to Novartis rejecting the patent application of its cancer drug Glivec. This was one of a more »

  • 6 Dow Stocks That Pay Double the Yield of the T-Bond: Part II

    By Meena Krishnamsetty - May 1, 2013 | Tickers: DD, GE, MRK

    In Part I of this series, we discussed three of the six Dow stocks that currently pay yields at least twice as high as that of a 10-year U.S. Treasury. Consisting of two telecoms and a tech giant—Verizon, AT&T and Intel, to be exact—it’s crucial to realize that there are three more players that offer similar income with a relatively stable growth picture.

    Let’s more »

  • Is All Well With These 4 Pharmaceutical Powerhouses?

    By Nauman Aly - April 30, 2013 | Tickers: LLY, GSK, MRK

    In the world of big pharmaceuticals, investors have come to realize that dividend income is traditionally steady, while the share price may or may not move a great deal other than when a new breakthrough drug has been approved. As is the case, share price can also oftentimes struggle. Those big pharmas that can keep promising new products on the forefront - while at the same time keeping their dividend payout more »

  • Will Merck's Dividends Continue to Produce Healthy Income for Investors?

    By Nauman Aly - April 30, 2013 | Tickers: LLY, GSK, MRK

    Throughout the years, some of the best performing pharmaceutical industry stocks have had long histories of providing healthy dividends to their stockholders. Merck (NYSE: MRK), for instance, a Big Pharma offering a number of healthcare solutions predominantly via its prescription meds, is well known for also providing a nice steady dividend income stream to its investors.


    Where Merck is headed

    In addition to its vaccines, biologic therapies, prescription drugs, and more »

  • Page 1 of 12